An Oklahoma judge ruled against Johnson & Johnson in a landmark opioid trial on Monday, ordering the company and subsidiary Janssen to pay $572 million. Attorneys for the state argued that the company’s marketing tactics contributed to Oklahoma’s opioid crisis. (MM&M)

The award was significantly less than some experts expected. Oklahoma had sought more than $17 billion in reimbursement for its opioid-related costs. J&J said it is planning to appeal the judge’s decision. (Bloomberg)

After mass shootings in El Paso, Texas, and Dayton, Ohio, this month, MM&M asked for your creative ideas to #InspireTheEnd of gun violence. In the latest edition of Chops, editor-in-chief Steve Madden shows off early inspiring submissions. (MM&M)

The Justice Department is planning to expand the number of marijuana farmers licensed to grow pot for authorized cannabis research. Lawmakers from both parties though the DOJ was taking too long to expand the verified research-pot-grower list. (Associated Press)

Amgen struck a deal to buy Celgene psoriasis treatment Otezla on Monday for $13.4 billion. The sale could be a step forward for Bristol-Myers Squibb’s planned $74 billion acquisition of Celgene because it could alleviate antitrust concerns. (Wall Street Journal)